Austria Drug Manufacturers - General news

23:21 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?

For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and …

LLYC mentioned NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

23:13 10 Aug 2026

nasdaq.com Regulatory and legal Main company 🇦🇹 Austria

Why Eli Lilly Topped the Market Today

Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly › Eli …

LLYC main company NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

22:39 10 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇦🇹 Austria

Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one …

LLYC mentioned NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

22:12 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough.

Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications. Continue Reading

NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +27.1% · Next-week setup positive 55.2%

21:01 10 Aug 2026

finance.yahoo.com Deals and strategy Provider-linked mention 🇦🇹 Austria

Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update

Lakefront Biotherapeutics Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash and financial investments balance guidance of ~€2B, and …

GILD mentioned

Sharemaestro market context Price below Trend Line 52 weeks +17.3% · Next-week setup positive 55.8%

20:58 10 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇦🇹 Austria

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) received UK authorization for Silver Upgrade …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

20:35 10 Aug 2026

finance.yahoo.com Earnings Main company 🇦🇹 Austria

Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and …

LLYC main company NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

19:07 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY

During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

19:02 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

S&P 500 Companies' Quarterly Earnings Growth Eases Amid Healthcare Drop, Oppenheimer Says

S&P 500 companies' quarterly earnings growth rate eased from a week ago amid a drop in the healthcar PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. …

MRK mentioned PFE mentioned

Sharemaestro market context Trend signal active 52 weeks +59.8%

18:53 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Jim Cramer Sees Cheap Valuation in Becton, Dickinson (BDX) After Q3 Beat and Raised Guidance

On August 6, Jim Cramer highlighted Becton, Dickinson and Company (NYSE:BDX) on CNBC's Mad Money following its third-quarter fiscal 2026 financial report and said: This morning, we got a very strong quarter from BD. That's the big medical technology and supply play... That was …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

18:40 10 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇦🇹 Austria

Sector Update: Healthcare Stocks Rise in Afternoon Trading

Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

18:37 10 Aug 2026

finance.yahoo.com Earnings Main company 🇦🇹 Austria

Bristol Myers Squibb to build $2.3 billion Houston campus

Bristol Myers Squibb announced Monday it will build a $2.3 billion drug manufacturing campus in Houston, Texas, part of the company's broader $40 billion commitment to invest in the United States over five years. The roughly 600,000-square-foot campus will be located at Generation Park, …

BMYS main company

Sharemaestro market context Trend signal active 52 weeks +41.2%

18:00 10 Aug 2026

finance.yahoo.com Regulatory and legal Provider-linked mention 🇦🇹 Austria

Glioma Market is Set for Tremendous Growth at a CAGR of 15% During the Study Period (2022–2036), as Novel Targeted Therapies and Immunotherapies are Gaining Momentum | DelveInsight

DelveInsight Business Research LLP The glioma market is expected to witness steady growth over the coming years, driven by the rising incidence of primary brain tumors, increasing awareness, and advances in diagnostic technologies. The market is also benefiting from a robust pipeline of therapies, …

PFE mentioned

Sharemaestro market context Price above Trend Line 52 weeks +13.3%

17:59 10 Aug 2026

finance.yahoo.com Earnings Main company 🇦🇹 Austria

AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use

AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +23.7%

17:44 10 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇦🇹 Austria

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after advancing into clinical development under its collaboration with Sanofi (SNY), RBC Capital Markets said in a Monday research note.The investment firm said limited preclinical data Silver Upgrade to read this MT …

SANO mentioned

Sharemaestro market context Trend signal started 52 weeks -4.9%

17:16 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum

Immunocore Holdings plc IMCR has gained 21.2% over the past 12 weeks, putting the durability of that advance in focus. Kimmtrak demand and late-stage pipeline progress give investors concrete operating and clinical milestones to watch. The stock's shorter-term gains have been more modest, while …

MRK mentioned

Sharemaestro market context Trend signal active 52 weeks +59.8%

16:41 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?

Immunocore Holdings plc IMCR offers a clear trade-off between commercial momentum and valuation risk. Kimmtrak continues to expand in metastatic uveal melanoma, while late-stage studies could open larger markets. The counterweight is equally clear. IMCR relies on one marketed product, trades above key industry …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

16:39 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss

Immunocore Holdings plc IMCR posted second-quarter 2026 revenues of $115.9 million, up 18.3% year over year and above the Zacks Consensus Estimate of $114 million. The company's loss of 2 cents per share, however, was wider than the consensus estimate of a loss of …

MRK mentioned

Sharemaestro market context Trend signal active 52 weeks +59.8%

16:38 10 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇦🇹 Austria

European Stocks Close Mixed in Monday Trading as Investors Monitor Middle East War Developments

The European stock markets closed mixed in Monday trading as investors continue to gauge development PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +27.1% · Next-week setup positive 55.2%

16:17 10 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇦🇹 Austria

How smart investors use ETFs to legally bypass IRS wash sale rules

Tax loss harvesting is a very effective strategy for investors to trim their tax bill each year. Selling underperforming holdings in a taxable account for a loss can help offset gains realized elsewhere. You can use losses to offset realized capital gains and can …

PFE mentioned

Sharemaestro market context Price above Trend Line 52 weeks +13.3%

16:15 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?

Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. …

MRK mentioned PFE mentioned

Sharemaestro market context Trend signal active 52 weeks +59.8%

15:23 10 Aug 2026

nasdaq.com Market update Main company 🇦🇹 Austria

Bristol Myers To Invest $2.3 Bln In Houston Manufacturing Campus; To Create 500 Skilled Jobs

(RTTNews) - Bristol Myers Squibb (BMY) announced Monday an investment of approximately $2.3 billion in the U.S., while selecting Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus to accelerate the delivery of next-generation medicines to patients. The approximately 600,000 square …

BMYS main company

Sharemaestro market context Trend signal active 52 weeks +41.2%

15:12 10 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇦🇹 Austria

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading

LLYC mentioned NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

15:00 10 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇦🇹 Austria

Lifespan Vision Ventures Leads Remedium Bio's Series A Financing

Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development. NORWALK, Conn., Aug. 10, 2026 /PRNewswire/ -- Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financing and has completed the round's initial …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

14:17 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength …

LLYC mentioned NNO2 mentioned PFE mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

13:42 10 Aug 2026

finance.yahoo.com Earnings Main company 🇦🇹 Austria

Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +52.0%

13:00 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

3 Beaten-Down Healthcare Stocks to Buy in August

Quick Read LLY grew Q1 revenue 56% and won FDA approval for the first oral GLP-1 pill, yet still trades 6% off its 52-week high. Healthcare has trailed SPY's 8% YTD gain, but JNJ's 64-year dividend streak and 20x forward P/E keep it compelling …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

11:32 10 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇦🇹 Austria

ChemoMetec enters collaboration agreement with Roche Diagnostics

Chemometec A/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today …

ROGH mentioned

Sharemaestro market context Price above Trend Line 42 weeks +35.0% · Next-week setup positive 57.1%

11:30 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Inc. -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027-- -- In June …

NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +27.1% · Next-week setup positive 55.2%

10:19 10 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇦🇹 Austria

Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date

(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that the FDA review of its apitegromab Biologics License Application for spinal Silver Upgrade to read …

NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +27.1% · Next-week setup positive 55.2%

06:00 10 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇦🇹 Austria

Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading

LLYC mentioned NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

02:31 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Amazon.com Inc.'s Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access. The company announced …

LLYC mentioned NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

00:33 10 Aug 2026

finance.yahoo.com Earnings Main company 🇦🇹 Austria

The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie's Q2 Earnings Call AbbVie's second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +23.7%

20:04 9 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Lineage Cell Therapeutics Q2 Earnings Call Highlights

Key Points Interested in Lineage Cell Therapeutics, Inc.? Here are five stocks we like better. Pipeline progress: Lineage advanced preclinical programs in corneal disease, Type 1 diabetes and hearing loss, while Roche and Genentech continued optimizing surgical delivery for the lead OpRegen retinal therapy. …

ROGH mentioned

Sharemaestro market context Price above Trend Line 42 weeks +35.0% · Next-week setup positive 57.1%

14:35 9 Aug 2026

nasdaq.com Deals and strategy Main company 🇦🇹 Austria

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.

Key Points Few companies have a longer track record of uninterrupted dividend growth. This streak is likely to be prolonged well into the foreseeable future. While still an income stock, Johnson & Johnson is also being priced somewhat like a growth stock.10 stocks we …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +52.0%

14:05 9 Aug 2026

seekingalpha.com Earnings Provider-linked mention 🇦🇹 Austria

Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus

Wall Street’s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P …

LLYC mentioned NNO2 mentioned PFE mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%